David Dai
Stock Analyst at UBS
(3.17)
# 3,069
Out of 5,182 analysts
40
Total ratings
51.52%
Success rate
2.44%
Average return
Main Sectors:
Stocks Rated by David Dai
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JANX Janux Therapeutics | Downgrades: Neutral | $57 → $15 | $15.23 | -1.51% | 2 | Apr 15, 2026 | |
| ASML ASML Holding | Maintains: Outperform | $1,911 → $1,971 | $1,432.44 | +37.60% | 3 | Mar 26, 2026 | |
| JSPR Jasper Therapeutics | Assumes: Neutral | $1.5 | $0.93 | +61.31% | 1 | Mar 23, 2026 | |
| CATX Perspective Therapeutics | Maintains: Buy | $7 → $8 | $4.27 | +87.35% | 3 | Mar 18, 2026 | |
| SONY Sony Group | Downgrades: Market Perform | $30 → $22 | $20.14 | +9.24% | 2 | Mar 17, 2026 | |
| KURA Kura Oncology | Maintains: Buy | $16 → $15 | $9.07 | +65.38% | 4 | Mar 13, 2026 | |
| IOVA Iovance Biotherapeutics | Maintains: Neutral | $2 → $4 | $3.43 | +16.62% | 3 | Mar 5, 2026 | |
| KYMR Kymera Therapeutics | Maintains: Buy | $90 → $128 | $86.68 | +47.67% | 1 | Mar 3, 2026 | |
| BNTX BioNTech SE | Maintains: Neutral | $115 → $117 | $102.06 | +14.64% | 1 | Nov 6, 2025 | |
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $35 → $38 | $21.00 | +80.95% | 3 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $114 → $132 | $104.04 | +26.87% | 3 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $23 → $20 | $10.40 | +92.31% | 1 | Sep 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $26 | $16.49 | +57.67% | 2 | Jul 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $30 | $22.12 | +35.62% | 1 | Jul 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $24 | $13.25 | +81.13% | 2 | May 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sell | $24 | $28.56 | -15.97% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $29.48 | +69.61% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $60 | $66.82 | -10.21% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $448 | $7.93 | +5,549.43% | 1 | Mar 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $131.45 | -69.57% | 1 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $3.05 | +1,211.48% | 1 | Feb 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $2.83 | +1,666.78% | 1 | Nov 18, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $41 → $52 | $29.75 | +74.79% | 1 | Mar 17, 2020 |
Janux Therapeutics
Apr 15, 2026
Downgrades: Neutral
Price Target: $57 → $15
Current: $15.23
Upside: -1.51%
ASML Holding
Mar 26, 2026
Maintains: Outperform
Price Target: $1,911 → $1,971
Current: $1,432.44
Upside: +37.60%
Jasper Therapeutics
Mar 23, 2026
Assumes: Neutral
Price Target: $1.5
Current: $0.93
Upside: +61.31%
Perspective Therapeutics
Mar 18, 2026
Maintains: Buy
Price Target: $7 → $8
Current: $4.27
Upside: +87.35%
Sony Group
Mar 17, 2026
Downgrades: Market Perform
Price Target: $30 → $22
Current: $20.14
Upside: +9.24%
Kura Oncology
Mar 13, 2026
Maintains: Buy
Price Target: $16 → $15
Current: $9.07
Upside: +65.38%
Iovance Biotherapeutics
Mar 5, 2026
Maintains: Neutral
Price Target: $2 → $4
Current: $3.43
Upside: +16.62%
Kymera Therapeutics
Mar 3, 2026
Maintains: Buy
Price Target: $90 → $128
Current: $86.68
Upside: +47.67%
BioNTech SE
Nov 6, 2025
Maintains: Neutral
Price Target: $115 → $117
Current: $102.06
Upside: +14.64%
Syndax Pharmaceuticals
Nov 4, 2025
Maintains: Buy
Price Target: $35 → $38
Current: $21.00
Upside: +80.95%
Oct 31, 2025
Maintains: Buy
Price Target: $114 → $132
Current: $104.04
Upside: +26.87%
Sep 23, 2025
Maintains: Buy
Price Target: $23 → $20
Current: $10.40
Upside: +92.31%
Jul 10, 2025
Maintains: Buy
Price Target: $30 → $26
Current: $16.49
Upside: +57.67%
Jul 1, 2025
Initiates: Buy
Price Target: $30
Current: $22.12
Upside: +35.62%
May 12, 2025
Maintains: Buy
Price Target: $30 → $24
Current: $13.25
Upside: +81.13%
Oct 24, 2024
Initiates: Sell
Price Target: $24
Current: $28.56
Upside: -15.97%
Oct 24, 2024
Initiates: Buy
Price Target: $50
Current: $29.48
Upside: +69.61%
Oct 24, 2024
Initiates: Buy
Price Target: $60
Current: $66.82
Upside: -10.21%
Mar 31, 2022
Initiates: Outperform
Price Target: $448
Current: $7.93
Upside: +5,549.43%
Mar 16, 2022
Initiates: Outperform
Price Target: $40
Current: $131.45
Upside: -69.57%
Feb 4, 2022
Initiates: Outperform
Price Target: $40
Current: $3.05
Upside: +1,211.48%
Nov 18, 2021
Initiates: Outperform
Price Target: $50
Current: $2.83
Upside: +1,666.78%
Mar 17, 2020
Upgrades: Outperform
Price Target: $41 → $52
Current: $29.75
Upside: +74.79%